Hutchmed Announces Licensing Agreement With GSK For Kras-Egfr-Antibody Conjugate Cancer Therapy
HCM•Licensing agreement with GSK
- HUTCHMED announces licensing agreement with GSK for KRAS-EGFR-antibody conjugate cancer therapy.
- HUTCHMED (China) said the agreement includes $110 million upfront, up to $1.30 billion in milestones, plus royalties.
